MedPacto Inc. researches, develops, and manufactures oncology therapeutics. The company offers TEW-7197 and TEW-0201, the anti-cancer drugs which help to suppress tumor growth; and DKK2, an angiogenesis-promoting protein which helps in the formation of blood vessels to cure ulcer or neuropathy caused by diabetes.
MedPacto, Inc.
Management
Technology
Deals/Partnering
Research Pipeline
Funding
BioStartup's Score
0 / 50
KEY DETAILS
Websitehttp://www.medpacto.com
Founded2013
Disease Focus
Development Stage
STOCK CODENon Listed
Address145 Gwanggyo-roAdvanced Institutes of Convergence Technology Building C, 5th floor, Room 50616229SuwonSouth Korea
145 Gwanggyo-roAdvanced Institutes of Convergence Technology Building C, 5th floor, Room 50616229
Suwon
South Korea
Contact Number+82-31-888-9928
+82-31-888-9928
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]